Cancer Immunotherapy
Addressing unmet needs in oncology with off-the-shelf, universal T cell treatments made from healthy donor cells
Gene Therapy
Working to create permanent cures by addressing medical conditions at the genome level
Precision BioSciences is a clinical stage biotechnology company dedicated to improving life with novel therapeutics that address unmet medical needs for patients living with cancer, rare disease, and other genetically defined medical conditions. Our proprietary genome editing platform, ARCUS, was designed with therapeutic safety and efficacy in mind. We have clinical trials for three “off-the-shelf” CAR T immunotherapy candidates and several pre-clinical in vivo gene correction programs underway, all with the goal of curing diseases for which no adequate treatments exist.
ARCUS is a gene editing enzyme. Gene editing is the process of directly modifying DNA to modify the function of a cellular component. Unlike traditional drugs that temporarily impact downstream biological events or gene therapies that rely on added DNA elements, gene editing works on the existing DNA within the cell. This generally requires a site-specific nuclease that can be designed to recognize and cut a unique DNA sequence within a target gene within the cell’s vast amount of genomic DNA. This stimulates the cell’s own DNA-repair machinery, which can generate a range of desired DNA sequence changes. Gene editing tools make changes to the DNA of treated cells and tissues that are retained and replicated when cells divide, enabling medicines that are extremely specific, effective, and long-lasting.
Recent News
As we navigate the unprecedented COVID-19 pandemic, we remain committed to the health and safety of our community including patients, employees, and our partners. Read more from Matt Kane, CEO and co-founder of Precision BioSciences.